-
SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Reshape Breast Cancer Neoadjuvant Therapy
Editor’s Note As CDK4/6 inhibitors (CDK4/6i) secure their role in adjuvant therapy for HR+/HER2− early breast cancer, a central clinical challenge has emerged: how to maximize benefit while minimizing toxicity…
-
SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Redefine Neoadjuvant Breast Cancer Treatment
Study Overview Background With intensified adjuvant CDK4/6i therapy, the absolute improvement in invasive disease-free survival (IDFS) ranges from 4.9% to 7.6%. Given treatment-related adverse events and economic burden, identifying patients…
-
SABCS China Voice | Professors Yan Min & Lü Huimin: U-BOMB-HER Study Advances Treatment of HER2-Positive Brain Metastases
PS5-01-13 — Utidelone Plus Bevacizumab for the Treatment of HER2-Positive Breast Cancer Brain Metastases (U-BOMB-HER): A Multicenter, Single-Arm Phase II Study Study Overview Background Although novel HER2-targeted agents, including tyrosine…
-
SABCS China Voice | Professor Yan Min’s Team: Post-PERMEATE Study Clarifies Radiotherapy Timing in HER2-Positive Brain Metastases
Editor’s Note: HER2-positive breast cancer has a high incidence of brain metastases. In the era when treatment relied primarily on local therapies, patient survival outcomes were poor. The PERMEATE study…
-
ASH Global Perspectives | Prof. Hanny Al-Samkari: Efficacy, Safety, and Dose Optimization of Ianalumab + Eltrombopag in Second-Line ITP
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder, and management after failure of first-line corticosteroid therapy remains a significant clinical challenge. In recent years, emerging therapies targeting key pathways involved…
-
ASH Global Perspectives | Professor Jeff Sharman: How Can We Reshape Treatment Strategies for Elderly Patients With DLBCL?
Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of lymphoma, but its management is particularly challenging in elderly patients. Standard R-CHOP chemotherapy is often poorly tolerated in…
-
ASH Global Perspectives | Prof. Fabio Efficace’s Team: Advances in Patient-Reported Outcomes in Hematology
In recent years, the field of hematologic malignancies has advanced at an unprecedented pace, with a steady emergence of novel therapies. While prolonging survival remains a central goal, patients’ quality…
-
New Breakthrough in Targeting BAFF Pathway: Ianalumab Significantly Prolongs Time to Treatment Failure in ITP Patients — A Detailed Look at VAYHIT 2
At the recently concluded American Society of Hematology (ASH) Annual Meeting in 2025, Dr. Hanny Al-Samkari from Massachusetts General Hospital presented the highly anticipated primary analysis of the VAYHIT 2 study. Presented as a Late-Breaking Abstract (LBA), this global, randomized, double-blind, Phase 3 clinical trial evaluated the efficacy and safety of combining the novel BAFF…
Connecting Medical Expertise through Media